Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.3.3.8: ATP citrate synthase

This is an abbreviated version!
For detailed information about ATP citrate synthase, go to the full flat file.

Word Map on EC 2.3.3.8

Reaction

ADP
+
phosphate
+
acetyl-CoA
+
oxaloacetate
=
ATP
+
citrate
+
CoA

Synonyms

ACL, ACL1, ACL2, ACLA, ACLB, ACLY, adenosine triphosphate citrate lyase, ATP citrate (pro-S)-lyase, ATP citrate lyase, ATP citrate lyase isoform 2, ATP-citrate lyase, ATP-citrate synthase A-2, ATP-citrate synthase alpha chain protein 2, ATP-citric lyase, ATP:citrate lyase, ATP:citrate oxaloacetate lyase ((pro-3S)-CH2COO--> acetyl-CoA) (ATP-dephosphorylating), ATP:citrate oxaloacetate-lyase (pro-3S-CH2COO->acetyl-CoA, ATP dephosphorylating), ATP:citrate oxaloacetate-lyase CoA-acetylating and ATP-dephosphorylating, Citrate cleavage enzyme, citrate-ATP lyase, citric cleavage enzyme, Earlier Degraded Tapetum1, EC 4.1.3.8, EDT1, Os11g0696200

ECTree

     2 Transferases
         2.3 Acyltransferases
             2.3.3 Acyl groups converted into alkyl groups on transfer
                2.3.3.8 ATP citrate synthase

Inhibitors

Inhibitors on EC 2.3.3.8 - ATP citrate synthase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-2,2-difluorocitrate
(-)-2,2-difluorocitrate
(-)-Hydroxycitrate
(1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid
-
50% inhibition at 0.00015 mM
(2E)-3-phenylprop-2-en-1-yl 2-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]benzoate
-
50% inhibition at 0.00034 mM
(2R)-2-[(2S)-8-(3,5-dichlorophenyl)-2-hydroxyoctyl]-2-hydroxysuccinic acid
-
50% inhibition at 0.0021 mM
(4S)-hydroxycitrate
-
-
1,3,8-trihydroxy-2-(3-methoxyphenyl)-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-2-(4-methoxyphenyl)-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-2-iodo-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(3-methylphenyl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(pyridin-3-yl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-phenylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[(morpholin-4-yl)methyl]anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[(piperidin-1-yl)methyl]anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[[methyl(phenyl)amino]methyl]anthracene-9,10-dione
-
-
1,3-dibromo-2,4,5-trihydroxy-7-methylanthracene-9,10-dione
-
-
1-chloro-2,4,5-trihydroxy-7-methylanthracene-9,10-dione
-
-
2,4,5-trihydroxy-7-methyl-1,3-di(pyridin-3-yl)anthracene-9,10-dione
-
-
2-chloro-1,3,8-trihydroxy-6-methylanthracen-9(10H)-one
-
-
2-chloro-1,3,8-trihydroxy-6-methylanthracene-9,10-dione
-
-
2-hydroxy-2-[(S-methylsulfonimidoyl)methyl]butanedioic acid
-
weak, reversible
3,3,14,14-tetramethylhexadecanedioic acid
-
i.e. Medica-16
3,5-dichloro-2-hydroxy-N-(4-methoxybiphenyl-3-yl)benzenesulfonamide
3,5-dichloro-N-(2,4,6-triphenyl-phenyl)-2-hydroxybenzenesulfonamide
-
50% inhibition at 0.00019 mM
3,5-dichloro-N-(3,5-di-tert-butylphenyl)-2-hydroxybenzenesulfonamide
-
50% inhibition at 0.0011 mM
3-(1,3-benzoxazol-5-yl)-5,7-dihydroxy-9-methyl-3,4-dihydro-2H-anthra[2,3-e][1,3]oxazine-6,11-dione
-
-
4-chloro-1,3,8-trihydroxy-6-methylanthracen-9(10H)-one
-
-
4-[[(2-hexyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 95% inhibition. 0.1 mM, 100% inhibition
-
4-[[(3,4-dibenzyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 3% inhibition. 0.1 mM, 64% inhibition
-
4-[[(3,4-dibenzyl-6-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 32% inhibition. 0.1 mM, 84% inhibition
-
4-[[(6-hexyl-2-oxo-4-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 53% inhibition. 0.1 mM, 92% inhibition
-
4S-hydroxycitrate
-
5,7-dihydroxy-9-methyl-3-phenyl-3,4-dihydro-2H-anthra[2,3-e][1,3]oxazine-6,11-dione
-
5-methyl-2-(1-methylethyl)cyclohexyl 2-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]benzoate
-
50% inhibition at 0.00037 mM
5-methyl-4-[[(2-oxo-4-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM,32% inhibition. 0.1 mM, 84% inhibition
-
5-methyl-4-[[(2-oxo-4-phenyl-6-propyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 97% inhibition. 0.1 mM, 97% inhibition
-
5-methyl-4-[[(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 45% inhibition. 0.1 mM, 101% inhibition
-
5-methyl-4-[[(4-methyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 17% inhibition. 0.1 mM, 90% inhibition
-
5-[(2,3-dimethylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 11% inhibition. 0.1 mM, 43% inhibition
-
5-[(4-fluoro-2-methylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 3% inhibition. 0.1 mM, 9% inhibition
-
5-[(4-fluorobenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 19% inhibition. 0.1 mM, 70% inhibition
-
5-[(4-methyl-3-nitrobenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM,21% inhibition. 0.1 mM, 89% inhibition
-
5-[(4-methylbenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 23% inhibition. 0.1 mM, 93% inhibition
-
5-[(benzenesulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 11% inhibition. 0.1 mM, 56% inhibition
-
5-[[(3,4-dibenzyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 9% inhibition. 0.1 mM, 49% inhibition
-
5-[[(4-methyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 18% inhibition. 0.1 mM, 88% inhibition
-
6,7-dibenzyl-2-methyl-5-[(4-methylbenzene-1-sulfonyl)amino]-1-benzofuran-3-carboxylic acid
0.01 mM, 12% inhibition. 0.1 mM, 42% inhibition
-
6,7-dibenzyl-5-[(4-ethylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 42% inhibition. 0.1 mM, 97% inhibition
-
6,7-dibenzyl-5-[(4-fluorobenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 28% inhibition. 0.1 mM, 95% inhibition
-
6,7-dibenzyl-5-[(4-tert-butylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 16% inhibition. 0.1 mM, 59% inhibition
-
bempedoic acid
BMS-303141
D-fructose 2,6-diphosphate
-
18% inhibition
D-glucose 6-phosphate
-
-
diethyldicarbonate
-
the addition of 0.5 mM ATP in the preincubation reaction mixture provided complete protection of enzyme activity from inactivation by diethyldicarbonate
DL-isocitrate
-
-
Fluorocitrate
-
-
GSSG
-
inactivation involves formation of a protein-protein disulfide rather than a protein-glutathione complex
Hydroxycitrate
L-Leu
-
2 mM, 20% inhibition
lauroyl-CoA
malonyl-CoA
-
0.4 mM, 70% inhibition
methyl 3-chloro-5-(N-(4,6-difluoro-[1,1'-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate
myristoyl-CoA
oleoyl-CoA
oxaloacetate
palmitoyl-CoA
radicicol
radicicol biotinylated at the C-17 position
-
no inhibition with the derivative biotinylated at the C-18 position
SB-201076
-
-
SB-204990
stearoyl-CoA
Tartrate
tricarballylate
-
-